First FDA Cleared treatment For Pediatric FAP/IBS


Large Global Market with Significant Unmet Need

Unique, Innovative Product Supported by Clinical Evidence

Clear Commercial Pathway

Seasoned Management and Board

How Does Neuromodulation Work?

NeurAxis Technology Is Better, Safer, And it Works

PENFS system intended for patients 11-18 years of age with functional abdominal pain (FAP) associated with IBS

Aids in pain reduction via neuromodulation to branches of Cranial Nerves (V,VII,IX and X)

Non-drug and non-surgical device therapy that can be placed in an outpatient clinic

Used 120 hours per week for up to 3-4 consecutive weeks*

NeurAxis’ IB-Stim™


Targeting An Over $9 Billion Addressable U.S. Market for pediatric Pipeline Indications


IB-Stim Research – By the Numbers™


IB-Stim™ Competitive Landscape


NeurAxis FDA Pipeline Indications


NeurAxis 2023 Go-To-Market Strategy


Collaborative Partnerships To Expedite Manufacturing


NeurAxis Is Leveraging An Impressive and Growing IP Portfolio


8 issued and 18 pending patents
– Device
– Method
U.S. IP runs through 2039 for now International IP in process Freedom to operate

NeurAxis Mission Is Accelerating


NeurAxis Opportunities in Play

Large Global Market with Significant Unmet Need

Unique, Innovative Product Supported by Clinical Evidence

Clear Commercial Pathway

Seasoned Management and Board

Sector Expertise Through Extraordinary Talent


8 issued and 18 pending patents
– Device
– Method
U.S. IP runs through 2039 for now International IP in process Freedom to operate


This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece., owned and operated by Jade Cabbage Media, LLC d/b/a makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold, or held by viewers that learn of the profiled companies through our website. 


Please review all investment decisions with a licensed investment advisor. This Advertorial was paid for in an effort to enhance public awareness of NeurAxis Inc. and its securities. Jade Cabbage Media, LLC d/b/a has received up to $10,000 USD dollars by Winning Media LLC as a total production budget for this advertising effort. Neither, Winning Media LLC or Jade Cabbage Media LLC currently hold the securities of NeurAxis Inc. and do not currently intend to purchase such securities. 


Winning Media LLC has been compensated the sum total of forty thousand dollars USD total production budget to manage a digital media campaign for fourteen days by One Eyed Jack Media LLC. on 8/23/23.


This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are several important factors that could cause actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues, and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. 


More information on the Company may be found at readers can review all public filings by the Company at the SEDAR and/or SEC’s EDGAR page. Jade Cabbage Media, LLC d/b/a is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.